ASCO GU 2025

What's the role of Enzalutamide in radioligand therapy?

Milestones of ADT and ARPI treatment in the metastastic prostate cancer

Combining ARPi with PARPi - discussing final OS of TALAPRO-2

Hypo-gonadism bad for survival?

Who benefits most from ARPIs?

ARPI for which patients?

Testosterone Recovery

Radiation vs surgery in high risk prostate cancer

Mevrometostat + Enza: New option for mCRPC

Local radiotherapy of oligoprogressive mCRPC

Mevrometostat - a new EZH2 inhibitor in mCRPC

ENZA-p showed OS benefit and improvement in QoL parameters

Improved Survival with Enzalutamide + Lutetium

Final OS data for TALA + Enza

Final OS analyses

Darolutamide + ADT reduces risk of progression or death by 46 % in mHSPC

OS in the TALAPRO-2 trial

MDT in OMPC

Darolutamide + ADT and Doetaxel improves survivas in mHSPC across age groups

Radical Prostatectomy VS RT in HRPC

Testosterone Recovery after ADT and OS

Phase 2 Mevrometostat

Fish-oil supplement for pts on active surveillance

Durvalumab in UTUC

Testosteron Geri Gelisi ve Sagkalim

Hangi hastalarda ADT+ARPI

Yuksek risk PCa da RP vs RT

UTUC de Neoadj. Durvalumab+Kemo

Oligometastatik PCa da MDT

Enza+Lu ile artmis sagkalim

Triplet combination in RCC - there's no free lunch with VEGFR

KIM-1 - The most interesting biomarker for RCC?

New data but no new conclusion

Exciting new substances - but don't over-estimate phase 1 data

AVION trial at mRCC

Firstline Update Kidney Cancer

New data nccRCC

Advanced Renal Cell Cancer: Adding more drugs does not translate in greater benefit

Casdatifan in refracting RCC

KIM-1 in CheckMate 214

KIM-1 in mRCC

Proactive coaching of patients with TKI +/- IO therapy

New agents / new mode of actions

Prognostic and predictive biomarkers in mRCC: Looking for the holy grail

Cáncer de células renales avanzado: añadir más fármacos no se traduce en un mayor beneficio

Biomarcadores prognósticos y predictivos en el CCRm: en busca del Santo Grial

Neoadjuvant chemo-immunotherapy in UTUC: new evidence for a challenging indication

New data, but no new insights for adjuvant treatment of high-risk MIBC patients

ADC + ICI - The future for MIBC?

Exploratory analyses of pCR in NIAGARA: who benefits most from perioperative Durvalumab?

Reassuring data on established ADCs and new insights in novel ADCs for urothelial cancer

ASCO GU 25 - Summary: Urothelial Cancer

Updates neo/adjuvant therapy in MIBC

Sacituzumab Tirumotecan shows promising antitumor activity in aUC after platinum-based therapy

Durvalumab + Platinum-based chemotherapy shows promising efficacy and safety in high-grade UTUC

HER2 - new marker for bladder preservation

New drugs in mUC: The active field of ADCs

Bladder-sparing approaches - are we there yet?

The role of ctDNA in bladder cancer

Neoadjuvant treatment for UTUC

Nivo adjuvant in MIBC - a new standard

New FGFR3 inhibitor

EV-Pembro continues to be the standard for mTCC

Promising combination for perioperative setting

Phase 2 Mevrometastat

Adjuvant Nivo - independent from previous therapy

A possible new standard for mUC

Preliminary results of neoadjuvant chemoimmunotherapy in UTUC

ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος

Nuevos fármacos en mUC: El campo activo de las ADCs

Promising combination for perioperative setting

Testicular cancer: Reinventing the wheel

RPLND in metastatic Seminoma

Metastatik seminomda Primer RPLND

Cáncer de testículo: reinventar la rueda